Healthy Inc > Blog > Levocetirizine BP/USP/IP
Posted on:

Is levocetirizine safe in breastfeeding?

In the pharmaceutical industry, Levocetirizine is a potent, non-sedating second-generation antihistamine. As a pharmacist and manufacturer, I view its safety profile as highly favorable for lactating women, though it is essential to distinguish between clinical research and conservative manufacturer labeling.

At your WHO-GMP facility in Mumbai, where you likely produce Levocetirizine 5 mg tablets, providing these evidence-based technical insights can significantly enhance your professional authority on digital platforms.

Clinical Safety Profile

The “safety” of Levocetirizine during breastfeeding is supported by several high-quality lactation studies:

  • Low Milk Transfer: Research (including a 2024 human lactation study) shows that the Relative Infant Dose (RID) is approximately 1.9%. Generally, any drug with an RID below 10% is considered compatible with breastfeeding.

  • Minimal Infant Exposure: The absolute infant dose via breast milk is merely 1.1 μg/kg daily, which represents negligible systemic exposure for the baby.

  • Preferred Choice: Clinical guidelines from the NHS and the British Society for Allergy and Clinical Immunology categorize Levocetirizine (and its racemic parent, Cetirizine) as preferred antihistamines for breastfeeding mothers.

Effect on Milk Supply

  • Established Lactation: At standard therapeutic doses (5 mg daily), Levocetirizine is unlikely to affect milk production once breastfeeding is well-established (usually 6–8 weeks postpartum).

  • Early Postpartum Risk: High doses of antihistamines can theoretically decrease prolactin levels. Caution is advised if lactation is not yet fully established or if the drug is combined with decongestants like Pseudoephedrine, which are known to reduce supply.

The Pharmacist’s “Technical Warning”

As you promote your pharmaceutical firm, providing these nuances is essential for professional authority:

  • FDA vs. Clinical Reality: The official FDA label for Levocetirizine states it is “not recommended” during breastfeeding. This is widely considered a conservative regulatory stance due to a lack of original clinical trial data, which is now being superseded by modern independent research confirming its safety.

  • Infant Monitoring: Mothers should be advised to monitor their infants for rare but possible side effects, such as unusual drowsiness, irritability, or poor feeding.

  • Timing Strategy: To further minimize exposure, advise mothers to take the medication immediately after a feeding to allow the drug concentration to peak and decline before the next session.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Non-Sedating” USP: On your multivendor marketplace, emphasize that Levocetirizine is the pure (R)-enantiomer of Cetirizine, offering the same relief at half the dose with significantly less sedation—a major selling point for active mothers.

  • Stability for Export: Levocetirizine is stable but moisture-sensitive. Utilizing Alu-Alu blister packaging ensures a 36-month shelf life, which is a critical requirement for export to Zone IVb tropical regions.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in international health tenders and for private B2B pharmacy networks.

Levocetirizine Tablets

Posted on:

What is Levocetirizine 5 mg tablet used for?

In the pharmaceutical industry, Levocetirizine Dihydrochloride 5 mg is a highly potent, third-generation non-sedating antihistamine. As a pharmacist and manufacturer, I view Levocetirizine as the refined, active R-enantiomer of Cetirizine. It offers higher affinity for $H_1$ receptors, which allows for a smaller dose (5 mg vs. 10 mg) and a significantly lower risk of drowsiness.

Primary Clinical Uses

  • Allergic Rhinitis: Effective for both seasonal (hay fever) and perennial allergies. It relieves symptoms like sneezing, rhinorrhea (runny nose), and nasal congestion.

    Allergic Conjunctivitis: Reduces red, itchy, and watery eyes caused by environmental allergens like pollen, dust mites, or pet dander.

  • Chronic Idiopathic Urticaria: The primary treatment for long-term hives and skin itching, providing relief from wheals and redness.

  • Allergic Dermatitis: Used to manage itching associated with eczema or insect bites.

Mechanism of Action: High-Affinity $H_1$ Blockade

Levocetirizine is an inverse agonist that targets the peripheral histamine $H_1$ receptors.

Selective Binding: It selectively binds to $H_1$ receptors, preventing histamine—the primary mediator of the “allergic cascade”—from attaching.

Stabilization: It stabilizes the receptor in its inactive state, reducing capillary permeability and decreasing the inflammatory response (swelling and mucus production).

Peripheral Action: Because it has low lipid solubility and is a substrate for the P-glycoprotein pump, it does not easily cross the blood-brain barrier, which is why it is “non-sedating” for most patients.

The Manufacturer’s Perspective: Formulation & Export

From a production and global trade standpoint, Levocetirizine 5 mg is a high-demand, high-volume “essential” product:

  • Enantiomeric Purity: As a WHO-GMP manufacturer, we ensure the complete separation of the (R)-enantiomer. This purity is what gives Levocetirizine its superior safety profile over older antihistamines.

  • Formulation Varieties: For your B2B marketplace, we manufacture these as Immediate Release (IR) tablets, Mouth Dissolving Tablets (MDT), and Syrups for pediatric export.

  • Stability for Global Trade: Levocetirizine is highly stable. We utilize Alu-Alu or high-barrier PVC/PVDC blister packaging to ensure a 36-month shelf life for export to Zone IVb regions (Africa and Southeast Asia).

  • Dossier Support: This is a staple for pharmacy chains and distributors. Our Mumbai facility provides full CTD/eCTD Dossiers to support international registration against the innovator (Xyzal).

Levocetirizine Tablets

Add to cart